Related Experiment Video
Updated: Jan 6, 2026

04:41
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
23.8K
Apolipoprotein E impairs amyloid-β fibril elongation and maturation
Tohidul Islam1, Anna L Gharibyan1, Solmaz A Golchin1
1Department of Medical Biochemistry and Biophysics, Umeå University, Sweden.
The FEBS Journal
|October 2, 2019
Summary
Apolipoprotein E (ApoE) inhibits Alzheimer's disease amyloid-beta (Aβ) fibril elongation, preventing mature amyloid formation. This mechanism impacts Aβ clearance and the generation of toxic Aβ assemblies in vivo.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) peptide depositions.
- Apolipoprotein E (ApoE) influences Aβ amyloid formation and AD pathology.
- APOE ε4 allele carriers have an increased risk for developing AD.
Purpose of the Study:
- To investigate the mechanism by which ApoE interferes with Aβ amyloid formation.
- To determine how ApoE affects Aβ fibril elongation and maturation.
Main Methods:
- Surface plasmon resonance (SPR) assays.
- Thioflavin-T (ThT) fluorescence assays.
Main Results:
- ApoE directly targets the elongation phase of Aβ fibril formation.
- ApoE interference effectively prevents the maturation of Aβ amyloids.
- A complex equilibrium involving ApoE, Aβ monomers, and existing fibrils dictates amyloid formation rates and alternative assembly production.
Conclusions:
- ApoE acts as a potent inhibitor of Aβ amyloid fibril elongation.
- The findings elucidate a novel mechanism influencing Aβ assembly dynamics in vivo.
- This mechanism may affect both the clearance of Aβ aggregates and the formation of cytotoxic species.
Related Concept Videos
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils
6.2K
6.2K
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736

